AR882 50 mg

DRUG2 trials

Sponsors

Arthrosi Therapeutics

Conditions

Arthritis, GoutyGoutGout ChronicHyperuricemia

Phase 3

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

CompletedNCT06439602

Arthrosi TherapeuticsArthritis, Gouty, Gout, Gout Chronic +1

Start: 2024-06-26End: 2026-04-10Updated: 2026-08-31

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

Active, not recruitingNCT06846515

Arthrosi TherapeuticsArthritis, Gouty, Gout, Gout Chronic +1

Start: 2025-03-11End: 2026-10-01Target: 750Updated: 2026-08-31